84. Sarcoidosis Clinical trials / Disease details


Clinical trials : 149 Drugs : 227 - (DrugBank : 81) / Drug target genes : 82 - Drug target pathways : 167

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02888080
(ClinicalTrials.gov)
December 19, 201616/8/2016Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary SarcoidosisA Multiple-dose, Subject and Investigator Blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885(Canakinumab) in Patients With Pulmonary SarcoidosisPulmonary SarcoidosisDrug: ACZ885;Drug: PlaceboNovartis PharmaceuticalsNULLCompleted18 Years80 YearsAll40Phase 2United States;Germany;Netherlands
2EUCTR2016-001255-49-NL
(EUCTR)
18/10/201620/07/2016Study of efficacy, safety and tolerability of ACZ885 (Canakinumab) in patients with pulmonary sarcoidosisA multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with pulmonary sarcoidosis Pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: ILARIS
Product Code: ACZ885
INN or Proposed INN: canakinumab
Novartis Pharma Services AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
38Phase 2United States;Germany;Netherlands
3EUCTR2016-001255-49-DE
(EUCTR)
15/08/201611/07/2016Study of efficacy, safety and tolerability of ACZ885 (Canakinumab) in patients with pulmonary sarcoidosisA multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with pulmonary sarcoidosis Pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: ILARIS
Product Code: ACZ885
INN or Proposed INN: canakinumab
Novartis Pharma Services AGNULLNot Recruiting Female: yes
Male: yes
38 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;Netherlands;Germany
4EUCTR2013-005333-21-NL
(EUCTR)
30/06/201508/01/2015Study of efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosisA multiple-dose, double-blind, placebo-controlled, parallel study to assess the efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis Pulmonary sarcoidosis
MedDRA version: 17.1;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: ILARIS
Product Name: Canakinumab
Product Code: ACZ885
INN or Proposed INN: Canakinumab
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
90United States;Netherlands